Status of NPF-QII after six years: Updates to the dataset
Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…Multiple system atrophy with motor fluctuations: A presynaptic disease variant?
Objective: To describe a case-series of Parkinsonian multiple system atrophy (MSAp) firstly diagnosed with Parkinson's disease (PD) due to clear-cut and severe l-dopa-induced motor fluctuations…Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience
Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations
Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…Pulmonary dysfunction in Parkinson’s disease: A feature of early disease?
Objective: To characterize the abnormalities in pulmonary function tests (PFT) in early-diagnosed PD patients and to assess their prognostic features 2 years after. Background: Pulmonary…Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease
Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…Treating Parkinson’s 2015–A nationwide survey of treatment responses and complications in 1000 Irish patients with Parkinson’s disease
Objective: To collect real-life data from a large cohort with Parkinson's disease (PD), with particular emphasis on drug regimens, motor complications, and quality of life…AntiParkinsonian treatment patterns and motor complications among patients with Parkinson´s disease in Estonia
Objective: To evaluate pharmacological treatment patterns in patients with Parkinson´s disease (PD), prevalence of motor complications, and factors associated with them. Background: Levodopa is the…
- « Previous Page
- 1
- …
- 22
- 23
- 24